Peptide Therapy Guide: What You Need to Know Before Starting

What Are Peptides?

Peptides are short chains of amino acids, the same building blocks that make up proteins. While proteins are typically composed of 50 or more amino acids folded into complex structures, peptides are smaller, usually between 2 and 50 amino acids long. Your body produces thousands of peptides naturally, and they serve as signaling molecules that tell your cells what to do.

Think of peptides as text messages between cells. They are small, specific, and carry targeted instructions. Some peptides tell your pituitary gland to release growth hormone. Others signal your immune cells to ramp up activity. Still others tell damaged tissue to start repairing itself. Because peptides are so specific in their actions, they can produce targeted effects with fewer systemic side effects than many conventional drugs.

Peptide therapy involves administering specific synthetic peptides (or bioidentical versions of naturally occurring peptides) to produce a desired physiological effect. This might mean boosting your body’s growth hormone production, accelerating healing after an injury, sharpening cognitive function, or supporting immune health ^[1].

How Peptide Therapy Works

Peptides work by binding to specific receptors on cell surfaces, triggering downstream signaling cascades. This is the same mechanism your body’s own peptides use. The synthetic peptides used in therapy are designed to mimic or amplify these natural signals.

Unlike hormones (which often produce broad, systemic effects), peptides tend to have more targeted actions. This specificity is one of the reasons peptide therapy has attracted so much interest. In theory, you can dial in a particular biological response without as many off-target effects ^[2].

That said, “targeted” does not mean “without side effects.” Every peptide has its own risk profile, and the long-term effects of many therapeutic peptides are still being studied. The fact that something is a naturally occurring molecule does not automatically make it safe at therapeutic doses.

Key Peptides by Category

Tissue Repair: BPC-157 and TB-500

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protein found in human gastric juice. In animal studies, BPC-157 has shown remarkable healing properties across a range of tissues, including tendons, ligaments, muscles, bone, and gut lining ^[3]. It appears to work by promoting angiogenesis (new blood vessel formation), modulating nitric oxide pathways, and interacting with the growth hormone system.

The animal data on BPC-157 is genuinely impressive. Studies in rats have shown accelerated healing of severed Achilles tendons, improved recovery from muscle injuries, and protection against NSAID-induced gut damage ^[4]. The challenge? There are virtually no published human clinical trials. Everything we know about BPC-157 comes from animal models and anecdotal clinical reports. This is a critical gap in the evidence.

TB-500 (Thymosin Beta-4) is a 43-amino-acid peptide that plays a role in cell migration, wound healing, and inflammation regulation. Like BPC-157, it has shown promising results in animal studies for tissue repair, particularly for cardiac tissue, corneal injuries, and skin wounds ^[5]. TB-500 and BPC-157 are often used together in clinical practice, though, again, human trial data is lacking.

Growth Hormone Secretagogues: CJC-1295, Ipamorelin, and Sermorelin

This category of peptides is designed to stimulate your pituitary gland to produce more growth hormone (GH). They do not replace growth hormone directly (as synthetic HGH does). Instead, they encourage your body to make more of its own. This distinction matters because it preserves the body’s natural pulsatile release pattern and feedback mechanisms ^[6].

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It increases GH secretion and has a long half-life, especially when combined with a drug affinity complex (DAC). Clinical studies have shown that CJC-1295 can increase GH and IGF-1 levels by 200 to 1,000 percent after multiple doses ^[7].

Ipamorelin is a growth hormone secretagogue that acts on the ghrelin receptor (GHS-R). It stimulates GH release with minimal impact on cortisol and prolactin levels, which makes it one of the “cleaner” options in this category ^[8]. It is often combined with CJC-1295 for a synergistic effect.

Sermorelin is another GHRH analog and was actually FDA-approved for treating growth hormone deficiency in children (though the commercial product has been discontinued). It remains available through compounding pharmacies and is used off-label for anti-aging and performance optimization ^[9]. Of the GH secretagogues, Sermorelin has the most clinical data supporting its safety and efficacy.

The common goals for using these peptides include improved body composition (more lean mass, less body fat), better sleep quality, faster recovery from exercise, and improved skin elasticity. Results typically take 3 to 6 months to become noticeable.

Cognitive Peptides: Selank and Semax

Selank is a synthetic peptide based on the naturally occurring immunomodulatory peptide tuftsin. Developed in Russia, it has been studied for its anxiolytic (anti-anxiety) and nootropic (cognitive-enhancing) effects. Clinical research (mostly conducted in Russia) suggests it can reduce anxiety without the sedation or dependency associated with benzodiazepines ^[10]. It is administered as a nasal spray.

Semax is a synthetic analog of ACTH (adrenocorticotropic hormone) fragments. It has been studied for neuroprotective effects, cognitive enhancement, and treatment of stroke. Russian clinical trials have shown benefits for attention, memory, and cognitive processing speed ^[11]. Like Selank, it is typically administered intranasally.

Both peptides are approved medications in Russia but are not FDA-approved in the United States. The research is promising but largely limited to Russian-language publications, which limits independent verification. Western researchers have called for more rigorous, independently replicated trials.

Immune Support: Thymosin Alpha-1

Thymosin alpha-1 (Ta1) is a naturally occurring peptide produced by the thymus gland that plays a key role in immune function. It has the most established clinical evidence of any peptide on this list. Ta1 is approved in over 35 countries for the treatment of hepatitis B and C, and it has been studied as an adjunct therapy for various cancers and immune deficiency states ^[12].

Ta1 works by modulating T-cell function and dendritic cell activity, enhancing the body’s ability to recognize and respond to infections and abnormal cells. During the COVID-19 pandemic, it was studied as a potential therapy for severe cases, with some retrospective studies suggesting improved outcomes in critically ill patients ^[13].

In the regenerative health space, Ta1 is often used to support overall immune function, particularly in patients with chronic infections, autoimmune conditions, or immune dysfunction related to chronic stress.

Skin and Cosmetic: GHK-Cu

GHK-Cu (copper peptide) is a naturally occurring tripeptide (three amino acids) bound to a copper ion. It is found in human plasma, saliva, and urine, with levels declining as you age. GHK-Cu has been shown to stimulate collagen synthesis, promote wound healing, and possess anti-inflammatory and antioxidant properties ^[14].

What makes GHK-Cu interesting is its gene-modulating activity. Studies have shown it can upregulate or downregulate over 4,000 genes, many of which are involved in tissue repair, stem cell biology, and antioxidant defense ^[15]. It is available as a topical cream, serum, or injectable. Most people start with topical formulations for skin health before considering injectable forms.

For skin rejuvenation, the evidence supporting GHK-Cu is reasonably strong, particularly for wound healing and skin remodeling. It is one of the better-studied cosmetic peptides.

Sexual Health: PT-141 (Bremelanotide)

PT-141 (bremelanotide) is unique on this list because it actually has FDA approval. Under the brand name Vyleesi, it was approved in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women ^[16]. It works through melanocortin receptors in the brain, which means it acts on desire and arousal at a central nervous system level rather than simply increasing blood flow (like Viagra or Cialis).

PT-141 is also used off-label for male sexual dysfunction, though its FDA approval is only for premenopausal women with HSDD. Side effects include nausea (which can be significant), flushing, and headache. It is administered as a subcutaneous injection about 45 minutes before sexual activity.

Weight Management: AOD-9604

AOD-9604 is a modified fragment of human growth hormone (specifically amino acids 177 to 191). It was developed to isolate the fat-burning effects of growth hormone without the growth-promoting or blood-sugar-raising effects ^[17]. In animal studies, AOD-9604 stimulated lipolysis (fat breakdown) and inhibited lipogenesis (fat formation).

The human clinical data on AOD-9604 is limited. A phase 2 clinical trial for obesity showed modest weight loss that did not reach statistical significance compared to placebo. Despite the underwhelming trial data, AOD-9604 remains popular in clinical practice, often used as part of broader weight management protocols. The TGA (Therapeutic Goods Administration) in Australia has approved AOD-9604 as a food-grade supplement, which is notable because few peptides have achieved any regulatory approval ^[18].

Administration Routes

How a peptide is delivered affects its bioavailability, onset of action, and practicality. Here are the main routes:

Subcutaneous Injection

This is the most common route for therapeutic peptides. A small insulin-type needle is used to inject the peptide into the fatty tissue just beneath the skin (usually the abdomen or thigh). Most patients learn to self-inject at home after initial instruction. Subcutaneous injection provides good bioavailability and relatively consistent absorption. Peptides like CJC-1295, Ipamorelin, BPC-157, and TB-500 are most commonly given this way.

Oral Administration

Oral peptides face a significant challenge: the digestive system is designed to break down proteins and peptides. Most peptides are degraded by stomach acid and enzymes before they can be absorbed. BPC-157 is a notable exception, as it appears to maintain activity when taken orally, likely due to its origin as a gastric peptide ^[3]. Some newer formulations use enteric coatings or other technologies to protect peptides during digestion.

Nasal Spray

Intranasal delivery is ideal for peptides targeting the brain, as it can partially bypass the blood-brain barrier through direct nose-to-brain transport. Selank and Semax are typically administered this way. Nasal delivery is also convenient and painless, making it popular with patients.

Topical Application

Topical peptides are mainly used for skin applications. GHK-Cu is the best-known topical peptide, available in serums and creams. Penetration through the skin is limited, so topical peptides work best for localized skin effects rather than systemic ones.

FDA Status and Legal Considerations

This is where things get complicated, and it is important to understand the current regulatory environment.

Very few peptides are FDA-approved drugs. PT-141 (bremelanotide/Vyleesi) is one. Thymosin alpha-1 is approved in many countries but not in the United States. Most other therapeutic peptides are not FDA-approved for any indication.

In the United States, many peptides have been available through 503A compounding pharmacies under the Federal Food, Drug, and Cosmetic Act. Compounding pharmacies can prepare medications that are not commercially available when prescribed by a licensed provider for an individual patient. This has been the primary legal pathway for peptide therapy in clinical practice.

However, the FDA has been tightening regulations on compounded peptides. In 2023 and 2024, the FDA added several popular peptides to its “category 2” list of substances that cannot be compounded due to safety concerns. BPC-157, in particular, was flagged because it lacks sufficient safety data from human clinical trials ^[19]. This regulatory environment is actively evolving, and the availability of specific peptides may change.

If you are considering peptide therapy, work with a licensed healthcare provider who obtains peptides from an accredited compounding pharmacy (look for PCAB accreditation). Avoid purchasing peptides from unregulated online sources, as these products may be contaminated, mislabeled, or contain incorrect dosages.

Safety Considerations

Peptide therapy, as a category, has a generally favorable safety profile. Because peptides are small and are metabolized relatively quickly, they tend to have fewer long-term safety concerns than many conventional drugs. But “generally favorable” does not mean “risk-free.”

Key safety considerations include:

• Lack of long-term human data: For many peptides (especially BPC-157 and TB-500), we simply do not have long-term human safety data. Animal studies are encouraging, but they do not always predict human outcomes.
• Growth hormone secretagogue risks: Chronically elevating GH and IGF-1 levels may increase cancer risk over the long term. The data is not definitive, but the concern is biologically plausible and should be taken seriously ^[20]. People with a personal or family history of cancer should discuss this carefully with their provider.
• Product quality: Peptides from unregulated sources may contain impurities, incorrect concentrations, or degraded compounds. Quality control is essential.
• Injection site reactions: Redness, swelling, and itching at injection sites are common and usually mild.
• Peptide-specific side effects: PT-141 commonly causes nausea. GH secretagogues can cause water retention, tingling, and increased appetite. Each peptide has its own side effect profile.
• Drug interactions: Some peptides may interact with medications or other supplements. Always disclose your full medication list to your provider.

Cost of Peptide Therapy

Peptide therapy is almost always an out-of-pocket expense. Insurance does not typically cover compounded peptides used for optimization or anti-aging purposes. Here are typical monthly costs:

• Growth hormone secretagogues (CJC-1295/Ipamorelin): $200 to $400/month
• BPC-157: $150 to $300/month
• TB-500: $200 to $350/month
• Thymosin alpha-1: $200 to $500/month
• Selank or Semax: $60 to $150/month
• GHK-Cu (topical): $40 to $120/month
• PT-141: $50 to $100 per dose (used as needed)
• AOD-9604: $200 to $400/month

Add in provider consultation fees ($150 to $500 for initial visits, $75 to $200 for follow-ups), lab work, and supplies, and the total investment can be significant. Some clinics offer monthly membership programs that bundle consultations, labs, and peptides for $300 to $600 per month.

What the Research Actually Shows

Let’s be straightforward about the evidence, peptide by peptide:

Strong clinical evidence: Thymosin alpha-1 (extensive clinical trial data for immune modulation, approved in 35+ countries). PT-141/bremelanotide (FDA-approved for HSDD, phase 3 clinical trial data). Sermorelin (formerly FDA-approved, solid clinical data for GH deficiency).

Moderate clinical evidence: CJC-1295 and Ipamorelin (human pharmacokinetic studies, clinical data on GH/IGF-1 elevation, but limited efficacy trials for specific health outcomes). GHK-Cu (strong in vitro and wound healing data, some clinical studies for skin applications).

Limited to preclinical evidence: BPC-157 (strong animal data, no published human clinical trials). TB-500 (similar to BPC-157, mostly animal data). AOD-9604 (one failed phase 2 obesity trial, TGA food-grade approval but limited efficacy data).

Mostly foreign clinical data: Selank and Semax (Russian clinical trials, limited independent replication in Western literature).

This does not mean the peptides with limited evidence do not work. It means we cannot be as confident about their effects, optimal dosing, and long-term safety. Many clinicians who prescribe these peptides report consistent positive outcomes in their patients, but clinical experience and published clinical trial data are not the same thing.

Finding a Qualified Provider

Choosing the right provider for peptide therapy is arguably more important than choosing the right peptide. Here is what to look for:

1. Medical degree and licensure: Work with a licensed physician (MD or DO), nurse practitioner, or physician assistant who is authorized to prescribe medications in your state.
2. Training in peptide therapy: Ask about their specific training. Organizations like the American Academy of Anti-Aging Medicine (A4M) and the Institute for Functional Medicine offer relevant training programs.
3. Pharmacy sourcing: Your provider should obtain peptides from a PCAB-accredited 503A or 503B compounding pharmacy. Ask them directly where they source their peptides.
4. Lab monitoring: A responsible provider will order baseline labs (at minimum, a complete metabolic panel, CBC, hormone levels, and IGF-1 for GH secretagogues) and recheck periodically during treatment.
5. Honest about the evidence: Be wary of providers who make sweeping claims about peptide benefits without acknowledging the limitations of the evidence. A good provider will explain what we know, what we do not know, and what the risks are.
6. Individualized protocols: One-size-fits-all peptide protocols are a red flag. Your provider should tailor the choice of peptide, dose, and duration to your specific goals, health history, and lab results.
7. Clear follow-up plan: You should know how often you will be seen, what labs will be monitored, and what outcomes you are tracking.

Practical Tips for Getting Started

If you and your provider decide peptide therapy is appropriate, here are some practical tips:

• Start with one peptide at a time. It is tempting to start a complex stack, but beginning with a single peptide lets you assess your response and identify any side effects clearly.
• Be patient. Many peptides, especially GH secretagogues, take weeks to months to produce noticeable results. Do not expect overnight changes.
• Store peptides properly. Most reconstituted peptides need refrigeration and have a limited shelf life. Follow your pharmacy’s storage instructions carefully.
• Track your progress. Keep notes on how you feel, your sleep quality, energy levels, body composition, and any side effects. This information helps your provider optimize your protocol.
• Do not skip labs. Regular blood work is essential to monitor both efficacy and safety, especially for GH secretagogues (monitor IGF-1, fasting glucose, and HbA1c).

The Bottom Line on Peptide Therapy

Peptide therapy represents a genuinely interesting area of medicine with real biological plausibility and, for some peptides, solid clinical evidence. It is not magic, and the field suffers from significant hype that outpaces the published data for many compounds.

The peptides with the strongest evidence (Thymosin alpha-1, PT-141, Sermorelin) have undergone rigorous clinical testing. Others, like BPC-157 and TB-500, have compelling preclinical data but lack the human trials needed to make definitive claims. The regulatory environment is shifting, and access to certain peptides may become more or less restricted over time.

If you are interested in peptide therapy, the most important steps are finding a qualified provider, using properly sourced products, monitoring your response with regular lab work, and maintaining realistic expectations about what peptides can and cannot do. Peptide therapy works best as part of an overall health strategy that includes nutrition, exercise, sleep optimization, and stress management.

Frequently Asked Questions

Does peptide therapy actually work?

It depends on the peptide. Thymosin alpha-1, PT-141, and sermorelin have real human clinical evidence for immune support, sexual desire, and growth hormone deficiency. Popular healing peptides like BPC-157 and TB-500 show strong animal results but have no published human trials, so those benefits remain unproven in people.

How much does peptide therapy cost?

Most peptides run about $150 to $600 per month, with GHK-Cu topicals as low as $40 and thymosin alpha-1 up to $500. You also pay provider consults ($150 to $500 initial, $75 to $200 follow-ups) and lab work. Clinic memberships can add $300 to $600 monthly, and insurance rarely covers compounded peptides.

Is peptide therapy safe, and what are the side effects?

As a category it has a generally favorable safety profile with fewer long-term concerns than many conventional drugs. Injection-site redness, swelling, and itching are common but usually mild. PT-141 often causes nausea, and GH secretagogues can cause water retention, tingling, and appetite increase. The bigger issues are missing long-term human data and impurities from unregulated sources.

How long does peptide therapy take to work?

Do not expect overnight changes. Growth hormone secretagogues typically take 3 to 6 months to become noticeable, and most peptides need weeks to months to produce results. Patience matters, and timelines vary by the specific peptide and the goal you are treating, whether that is recovery, growth hormone optimization, or skin health.

Who is peptide therapy for?

People pursue it for tissue repair and healing of tendons, ligaments, muscle, and bone, growth hormone optimization, cognitive performance, immune support, weight management, skin rejuvenation, and sexual wellness. Specific conditions mentioned include hepatitis B and C, hypoactive sexual desire disorder, and growth hormone deficiency. It always warrants a licensed provider given the variability in evidence.

Are peptides legal and FDA-approved?

A few are approved, such as PT-141 for hypoactive sexual desire disorder, and sermorelin was formerly approved. Most are not FDA-approved for how they are commonly used. Many came through 503A compounding pharmacies, but in 2023 and 2024 the FDA restricted several, including BPC-157, for lacking human safety data. Injectables require a prescription.

References

1. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122-128. doi:10.1016/j.drudis.2014.10.003
2. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700-2707. doi:10.1016/j.bmc.2017.06.052
3. Sikiric P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert’s cytoprotection, Selye’s stress response, and Szabo’s pharmacological gastric cytoprotection. Curr Pharm Des. 2020;26(25):3020-3049. doi:10.2174/1381612826666200521114902
4. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066
5. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793
6. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. doi:10.1016/j.sxmr.2017.02.004
7. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhatt GR. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
8. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
9. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. doi:10.2147/ciia.2006.1.4.307
10. Zozulya AA, Gabaeva MV, Sokolov OY, Surkina ID, Kost NV. Personality, coping style, and constitutional neuroimmunology. J Immunotoxicol. 2008;5(2):221-225. doi:10.1080/15476910802131444
11. Eremin O, Stoyanova V, Grigorova P, Boyanova S, Dojnov P. Semax: neuroprotective and nootropic peptide review. Neuropeptides. 2019;73:1-8. doi:10.1016/j.npep.2018.11.002
12. Tuthill C, Rios I, McBeath R. Thymosin alpha 1: past clinical experience and future promise. Ann N Y Acad Sci. 2010;1194:130-135. doi:10.1111/j.1749-6632.2010.05482.x
13. Liu Y, Pang Y, Hu Z, et al. Thymosin alpha 1 reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells. Clin Infect Dis. 2020;71(16):2150-2157. doi:10.1093/cid/ciaa630
14. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108
15. Pickart L, Vasquez-Soltero JM, Margolina A. The effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline. Brain Sci. 2017;7(2):20. doi:10.3390/brainsci7020020
16. Kingsberg SA, Clayton AH, Pfaus JG. The female sexual response and the pathophysiology of hypoactive sexual desire disorder. J Sex Med. 2015;12(suppl 8):S219-S227. doi:10.1111/jsm.13033
17. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522
18. Stier H, Voss E, Kenington S. Safety and tolerability assessment of AOD9604 in healthy older overweight or obese adults. J Endocrinol Metab. 2013;3(1-2):7-13. doi:10.4021/jem.v3i1-2.155
19. U.S. Food and Drug Administration. Drugs that present demonstrable difficulties for compounding. FDA Bulk Drug Substances Advisory Committee. Updated 2024. Available at: https://www.fda.gov/drugs
20. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol (Oxf). 2006;64(2):115-121. doi:10.1111/j.1365-2265.2005.02404.x
21. PRP Therapy Guide: What You Need to Know About Platelet-Rich Plasma
22. NAD+ Dosage Guide: IV, Injection, and Oral Protocols Compared
23. GAINSWave Therapy for ED: How Shockwave Treatment Works
24. SIBO Natural Treatment: Herbal Antimicrobials and Evidence-Based Protocols

About the medical reviewer

Dr. Bronwyn Holmes, MD, FAARFM is a physician specialising in regenerative medicine, advanced peptide therapeutics, exosome and stem cell biology, hormonal health, and longevity. Last reviewed July 5, 2026.